Nephro Care Quarterly Results
Nephro Care quarterly results. In Sept 2026, Nephro Care (NEPHROCARE) reported revenue ₹33 Cr and net profit ₹3 Cr — revenue +43.5% YoY. View NEPHROCARE 52-week performance for the annual high/low range and current price position.
NEPHROCARE Quarterly Results — Revenue, Profit & EPS Highlights
Nephro Care latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Nephro Care share price performance to track price trends across different timeframes.
- Revenue of ₹33 Cr in Sept 2026 (+17.9% vs Mar 2026, +43.5% vs Sept 2025)
- Net Profit of ₹3 Cr in Sept 2026 (+200.0% vs Mar 2026, +0.0% vs Sept 2025)
- EBITDA of ₹5 Cr in Sept 2026 (+66.7% vs Mar 2026)
- Operating Margin of 15.0% in Sept 2026 (+7.0pp vs Mar 2026)
- Earnings Per Share of ₹1.67 in Sept 2026 (+173.8% vs Mar 2026)
Nephro Care Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NEPHROCARE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 33 | 28 | 29 | 23 | 17 | 17.9% | 43.5% |
| Net Profit (₹ Cr) | 3 | 1 | 2 | 3 | -1 | - | - |
| EBITDA (₹ Cr) | 5 | 3 | 4 | 4 | 1 | - | - |
| EPS (₹) | 1.67 | 0.61 | 0.98 | 1.57 | -0.39 | - | - |
| Operating Margin (%) | 15.0% | 8.0% | 12.0% | 17.0% | 3.0% | - | - |
NEPHROCARE Share Price Trend — 1-Year Movement Across Quarterly Results
Nephro Care 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Nephro Care share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NEPHROCARE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nephro Care latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1884.9 | 16,617 | 1,995 | +10.6% | - | 12.0% | 227.1 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11180.5 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4689.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 407.4 |
|
Apollo Hospitals
Sept 2026 |
₹132,281.88 Cr | 9200.0 | 7,673 | 660 | +15.2% | - | 8.6% | 209.9 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2294.6 | 2,219 | 436 | +21.7% | - | 19.6% | 280.9 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores